Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks

HIV Medicine

Volumn 9, Issue 8, 2008, Pages 642-652

  Kjær, Jesper ^a   Hoj L ^a   Fox, Z ^a   Lundgren, J D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Genotype; Neural networks; Phenotype; QSAR; Resistance prediction

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ARTIFICIAL NEURAL NETWORK; COMPUTER PREDICTION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DATA MINING; EXTERNAL VALIDITY; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INTERNAL VALIDITY; NONHUMAN; PHENOTYPE; PHYSICAL CHEMISTRY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; VALIDATION PROCESS; VIRUS MUTATION;

AMINO ACIDS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; NEURAL NETWORKS (COMPUTER); PHENOTYPE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 52649119802     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00612.x     Document Type: Article

References (30)

1. Baxter JD, Mayers DL, Wentworth DN et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 16: F83-F93.
2. Cingolani A, Antinori A, Rizzo MG et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002; 16: 369-379.
3. Cohen CJ, Hunt S, Sension M et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-588.
4. Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT Randomised Controlled Trial. Lancet 1999; 353: 2195-2199.
5. Meynard JL, Vray M, Morand-Joubert L et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002; 16: 727-736.
6. Tural C, Ruiz L, Holtzer C et al. Clinical utility of HIV-1 genotyping and expert advice: The Havana Trial. AIDS 2002; 16: 209-218.
7. Been-Tiktak A, Korn K, Keulen W et al. Evaluation of an open expert-based genotype interpretation program: RetroGram. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 2001 [Abstract I-1745].
8. Agence Nationale de Recherches sur le SIDA (ANRS). ANRS Genotypic Resistance Guidelines - version 13. http://www.hivfrenchresistance.org/ 2005.
9. De Luca A, Vendittelli M, Boldini F et al. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes. Antivir Ther 2004; 9: 583-593.
10. MacArthur RD. An updated guide to genotype interpretation. AIDS Reader 2004; 14: 256-266. http://dmchiv.wayne.edu/.
11. Ormaasen V, Sandvik L, Asjo B, Holberg-Petersen M, Gaarder PI, Bruun JN. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy. HIV Med 2004; 5: 400-406.
12. Retrovirology Laboratory Luxembourg. Centre Hospitalier Luxembourg. http://www.ablsa.com/site/en/product_vs.html 2003.
13. Shafer RW, Rhee SY, Zioni R et al. HIV Drug Resistance Database. http://hivdb.stanford.edu/pages/asi/releaseNotes/ 2006.
14. Vercauteren J, Van Laethem K, Deforche K, Camacho R, Vandamme A. REGA genotypic resistance interpretation system - version 6.4. http://www.kuleuven.ac.be/rega/cev/links/rega_algorithm/index.htm 2004.
15. Vandamme AM, Sonnerborg A, It-Khaled M et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9: 829-848.
16. De Luca A, Perno CF. Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. Curr Opin Infect Dis 2003; 16: 573-580.
17. Kijak GH, Rubio AE, Pampuro SE et al. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med 2003; 4: 72-78.
18. Sturmer M, Doerr HW, Staszewski S, Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 2003; 8: 239-244.
19. Braun P, Helm M, Ehret R et al. Predictive value of different drug resistance interpretation systems in therapy management of HIV-infected patients in daily routine. Antivir Ther 2002; 7: S102.
20. Cabrera C, Cozzi-Lepri A, Phillips AN et al. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA Study. Antivir Ther 2004; 9: 787-800.
21. De Luca A, Antinori A, Di Giambenedetto S et al. Interpretation systems for genotypic drug resistance of HIV-1. Scand J Infect Dis Suppl 2003; 106: 29-34.
22. Snoeck J, Kantor R, Shafer RW et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006; 50: 694-701.
23. Ravela J, Betts BJ, Brun-Vezinet F et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003; 33: 8-14.
24. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: The virtual phenotype (VirtualPhenotype). Antiviral Ther 2000; 5(Suppl. 3) [Abstract 63].
25. Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA 2006; 103: 17355-17360.
26. Zhang J, Rhee SY, Taylor J, Shafer RW. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr 2005; 38: 439-444.
27. Kawashima S, Ogata H, Kanehisa M. AAindex: Amino acid index database. Nucleic Acids Res 1999; 27: 368-369.
28. Nørgaard M. Neural network based system identification toolbox. [Report no.: Tech. report 00-E-891]. Lyngby: Department of Automation, Technical University of Denmark, 2000.
29. Wang D, Larder B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis 2003; 188: 653-660.
30. Beerenwinkel N, Daumer M, Oette M et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003; 31: 3850-3855.